Coronary heart disease (CHD) is the leading cause of death in the United Kingdom in men and women. It is also a major cause of premature death, accounting for 40% of deaths in men between the ages of 45 and 64 years. CHD imposes high social costs in terms of impaired quality of life and reduced economic activity and consumes a large share (2-5%) of NHS resources.' Cholesterol screening and cholesterol lowering programmes are promoted as a way of reducing mortality rates. This paper summarises a review of this strategy.2
Approaches to prevention Two main approaches to preventing CHD have been identified: those aimed at the whole population (population approach) and those aimed at individuals who are judged to be at highest risk of developing the disease (high risk approach).
Most clinical efforts have been directed at the high risk approach, which uses cholesterol concentration as the key measure in risk factor screening in order to identify those subjects to be treated. In mass risk factor screening all adults have their blood cholesterol concentration measured, and those subjects with high concentrations (according to criteria laid down by guidelines) are then considered to be at higher risk. Alternatively, doctors may routinely measure cholesterol concentration when patients consult for conditions unrelated to any known risk factors -that is, they may perform opportunistic screening.
Cholesterol screening and cholesterol lowering interventions are being strongly promoted, and both the public and doctors are coming under increasing pressure to measure blood cholesterol concentration. In order to evaluate the likely benefits of such a policy four areas will be examined: the ability of cholesterol measurements to predict the risk of CHD accurately; the accuracy of the measurements; the likely effectiveness of cholesterol lowering interventions in reducing mortality from CHD; and, lastly, the other effects of screening.
USE OF CHOLESTEROL CONCENTRATION IN PREDICTING INDIVIDUAL RISK
Even though serum total cholesterol concentration is an important risk factor for CHD in populations, it is poor at discriminating between individual subjects who will or will not progress to CHD without treatment. Data from the Framingham study illustrate the considerable overlap in the distribution of cholesterol concentration in men aged 30-49 who subsequently had different histories of CHD (fig 1) . 8 This overlap illustrates that those people who progress to a CHD event are not a distinct group, and the relation between cholesterol concentration and CHD is not dichotomous but continuous. The use of labels (for example, high cholesterol concentration) and cut off cholesterol concentrations provide a way of labelling patients more for the sake of "operational convenience" than as a reflection of the underlying process of CHD.9
Therefore the predictive accuracy of cholesterol measurement is very low. For example, of the men aged 35-57 with the highest 20% of the distribution of cholesterol concentration less than 1% will die of a heart attack in the next six years. This proportion rises to only about 2% in men with high blood pressure who also smoke.7 In other words, cholesterol concentration alone is a poor predictor of death from CHD. As the cut off value for cholesterol screening is lowered so a greater proportion of people will be wrongly categorised as at high risk.
ACCURACY OF MEASUREMENT
The main screening test is the measurement of total serum cholesterol concentration in blood 
EFFECTIVENESS OF CHOLESTEROL LOWERING INTERVENTIONS
Though serum total cholesterol concentration is a risk factor for CHD it cannot be assumed that intervening to reduce the concentration in people with raised serum cholesterol concentration is beneficial since the effects may be irreversible and the treatments may have adverse side effects which attenuate any other benefit. As has been stated: "Screening programmes in which doctors approach apparently healthy individuals to make them patients for a lifetime, ethically must ensure that treatment facilities are available, that treatment is of proven efficacy, and that it does more good than harm." '6 To assess reliably the effectiveness of intervening to reduce serum cholesterol concentration the results of randomised controlled trials must be examined. Most of these are too small to allow any reliable estimate of the effects of treatment on deaths due to CHD, other causes of death, and total mortality. Therefore the results of these trials need to be pooled in a quantitative overview (meta-analysis).
Previous meta-analyses have not taken into account the large variations in risk of CHD between study populations and therefore have not presented a clear picture of the likely benefits consequent on lowering serum cholesterol concentration. Recently, as part of the research for the Effective Health Care Bulletin, a new meta-analysis was carried out which stratified studies by risk of death from CHD. Published and unpublished data from all identified randomised controlled trials of cholesterol lowering with six months' follow up or more and with at least one death were included in the meta-analysis, the results of which are reported in detail elsewhere.'7 The meta-analysis shows that the magnitude, and even existence, of net benefit is strongly dependent on the initial level of risk of CHD. Net benefit from cholesterol lowering in terms of total mortality was seen only for trials which included patients with considerably raised initial risks of CHD (odds ratio 078 (95% confidence interval 063 to 095)). In the medium risk group there is no benefit from treatment and in the low risk group the total mortality among those treated was significantly raised (odds ratio (1 05 to 1-42)) (see fig 2) .
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